Search results for "prostate cancer."

showing 10 items of 410 documents

External photon radiation treatment for prostate cancer: Uncomplicated and cancer-free control probability assessment of 36 plans

2019

[Purpose] To perform a systematic and thorough assessment, using the Uncomplicated and Cancer-Free Control Probability (UCFCP) function, of a broad range of photon prostate cancer RT treatments, on the same scenario (a unique pelvic CT set). UCFCP considers, together with the probabilities of local tumour control (TCP) and deterministic (late) sequelae (NTCP), the second primary cancer risk (SPCR) due to photon and neutron peripheral doses.

MaleProbability assessmentmedicine.medical_treatmentRadiobiological modellingBiophysicsGeneral Physics and AstronomyProstate radiotherapy treatmentNormal tissue complication probabilityTumour control probabilityRadiation protection of the patient030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicinemedicineHumansDosimetryRadiology Nuclear Medicine and imagingConformal radiationProbabilityPhotonsbusiness.industryRadiotherapy Planning Computer-AssistedCancer-FreePhoton radiationProstatic NeoplasmsRadiotherapy DosageGeneral MedicineSecond primary cancermedicine.diseaseRadiation therapySecond primary cancer risk030220 oncology & carcinogenesisRadiotherapy plan optimisationRadiotherapy Intensity-ModulatedRadiotherapy ConformalTomography X-Ray ComputedNuclear medicinebusinessPhysica Medica 66: 88-96 (2019)
researchProduct

Polymorphisms of an innate immune gene, toll-like receptor 4, and aggressive prostate cancer risk: a systematic review and meta-analysis.

2014

Background: Toll-like receptor 4 (TLR4) is one of the best known TLR members expressed on the surface of several leukocytes and tissue cells and has a key function in detecting pathogen and danger-associated molecular patterns. The role of TLR4 in the pathophysiology of several age-related diseases is also well recognized, such as prostate cancer (PCa). TLR4 polymorphisms have been related to PCa risk, but the relationship between TLR4 genotypes and aggressive PCa risk has not been evaluated by any systematic reviews. Methods: We performed a systematic review and meta-analysis of candidate-gene and genome-wide association studies analyzing this relationship and included only white populatio…

MaleProstate cancer polymorphisms of TLR4 aggressive prostate cancer risk meta-analysisSystematic Reviewslcsh:MedicineGenome-wide association studySingle-nucleotide polymorphismBiologyResearch and Analysis MethodsBioinformaticsPolymorphism Single NucleotideProstate cancerGenotypeGeneticsCancer GeneticsmedicineHumansSettore MED/05 - Patologia ClinicaGenetic Predisposition to DiseaseStatistical Methodslcsh:ScienceGenotypingGenetic associationEvolutionary BiologyMultidisciplinarylcsh:RProstatic NeoplasmsBiology and Life SciencesResearch Assessmentmedicine.diseaseImmunity InnateToll-Like Receptor 4Systematic reviewMeta-analysisPhysical SciencesGenetic Polymorphismlcsh:QPopulation GeneticsMathematicsStatistics (Mathematics)Genome-Wide Association StudyResearch ArticleMeta-AnalysisPLoS ONE
researchProduct

Relative advantages and disadvantages of radical perineal prostatectomy versus radical retropubic prostatectomy

2002

In recent years prostate cancer has become the predominant malignancy in men. With the introduction of prostate specific antigen (PSA) the disease can be diagnosed at an early stage, at which surgical therapy can be curative. In the past century, the retropubic and the perineal routes were established as alternatives of surgical access to the gland for clinically localized prostate cancer. The selection of the operative route is mostly decided individually on the basis of surgical training and experience. The revived interest in perineal radical prostatectomy is explained by the fact that this technique has been associated with low morbidity. The differences of both surgical approaches of r…

MaleProstatectomymedicine.medical_specialtyProstatectomybusiness.industryContraindicationsmedicine.medical_treatmentProstatic NeoplasmsHematologyPerineumMalignancymedicine.diseasePerineumSurgeryProstate-specific antigenProstate cancerPostoperative Complicationsmedicine.anatomical_structureOncologyProstatemedicineHumansbusinessRadical perineal prostatectomyRadical retropubic prostatectomyCritical Reviews in Oncology/Hematology
researchProduct

A curved Lowsley retractor improves manoeuvrability of the prostate during ascending radical retropubic prostatectomy

2007

Worldwide, radical retropubic prostatectomy is the commonest surgical procedure for treating localized prostate cancer. The technique has evolved continuously over the years, yielding improved continence and potency while reducing considerably the associated complications. Simple surgical ‘tricks’ have been proposed for crucial steps, e.g. the control of the dorsal venous complex, atraumatic dissection of the neurovascular bundles (NVBs), improved visualization of the urethral stump and tailoring of the vesicourethral anastomosis [1,2].

MaleProstatectomymedicine.medical_specialtybusiness.industryProstatectomyUrologymedicine.medical_treatmentUrologyProstatic NeoplasmsNeurovascular bundlemedicine.diseaseRetractorDissectionProstate cancermedicine.anatomical_structureProstateMedical IllustrationVesicourethral anastomosisHumansMedicinebusinessRadical retropubic prostatectomyBJU International
researchProduct

Clinical intervals and diagnostic characteristics in a cohort of prostate cancer patients in Spain: a multicentre observational study

2015

BACKGROUND: Little is known about the healthcare process for patients with prostate cancer, mainly because hospital-based data are not routinely published. The main objective of this study was to determine the clinical characteristics of prostate cancer patients, the, diagnostic process and the factors that might influence intervals from consultation to diagnosis and from diagnosis to treatment. METHODS: We conducted a multicentre, cohort study in seven hospitals in Spain. Patients' characteristics and diagnostic and therapeutic variables were obtained from hospital records and patients' structured interviews from October 2010 to September 2011. We used a multilevel logistic regression mode…

MalePròstata -- Càncer -- DiagnosiEspaña:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Cohort StudiesProstate cancerInterquartile rangePrevalence:Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms Glandular and Epithelial::Carcinoma::Adenocarcinoma [Medical Subject Headings]UrologiaStage (cooking)MasculinoProspective cohort studyEarly Detection of Cancer:Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Neoplasm Grading [Medical Subject Headings]General MedicineHumanosCohortCritical PathwaysMale urogenital diseasesEducational StatusProstatic neoplasmsCohort studyCohort studyEmploymentmedicine.medical_specialtyUrology:Check Tags::Male [Medical Subject Headings]Clasificación del TumorNeoplasias de la PróstataAdenocarcinomaMulticentre studyTime-to-Treatment:Diseases::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms Male::Prostatic Neoplasms [Medical Subject Headings]Age DistributionInternal medicinemedicineHumansProspective studyAgedGynecologybusiness.industryResearchMale urogenital diseasesCancerProstatic NeoplasmsOdds ratiomedicine.diseaseReproductive MedicineSpainbusiness
researchProduct

Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: Who, when, where and how?

2014

Even in the current era of dose-escalated radiotherapy for prostate cancer, biochemical recurrence is not uncommon. Furthermore, biochemical failure is not specific to the site of recurrence. One of the major challenges in the management of prostate cancer patients with biochemical failure after radiotherapy is the early discrimination between those with locoregional recurrence only and those with metastatic disease. While the latter are generally considered incurable, patients with locoregional disease may benefit from emerging treatment options. Ultimately, the objective of salvage therapy is to control disease while ensuring minimal collateral damage, thereby optimizing both cancer and t…

MaleQuality ControlOncologyBiochemical recurrencemedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.medical_treatmentBrachytherapyBrachytherapySalvage therapyBone Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineAdenocarcinomaRadiosurgeryMultimodal Imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicineManagement of prostate cancerProstate cancerInternal medicinemedicineHumansMulticenter Studies as TopicRadiology Nuclear Medicine and imagingComputingMilieux_MISCELLANEOUSProstatectomySalvage TherapyLymphatic Irradiationbusiness.industryPalliative CareProstatic NeoplasmsCancerAndrogen AntagonistsRadiotherapy DosageProstate-Specific Antigenmedicine.diseaseCombined Modality Therapy3. Good healthRadiation therapyProstate-specific antigenOncologyLymphatic MetastasisDose Fractionation RadiationRadiotherapy Intensity-ModulatedNeoplasm Recurrence LocalbusinessRadiotherapy Image-Guided
researchProduct

Overall survival in mCPRC patients treated with Radium-223 in association with bone health agents: a national multicenter study

2020

Radium-223 has demonstrated efficacy in improving overall survival (OS) and in delaying symptomatic skeletal-related events (SREs). Bone Health Agents (BHA), i.e. RANK ligand inhibitor (Denosumab) and bisphosphonate such as zoledronic acid, are indicated to prevent SREs without a clear survival benefit. SREs on patient health have a high impact and it is, therefore, important to consider the role of new therapies with BHA to better understand the involvement of combination therapy. The primary aim of this multicentric study is to assess OS in mCRPC patients treated with Radium-223 in combination with BHA.430 consecutive patients treated with Radium-223 alone or in combination with BHA, affe…

MaleRadium-223Oncologymedicine.medical_specialtyRadium-223 dichlorideRadium-223 dichloride; bone health agents; mCRPC; overall survival; prostate canceroverall survivalBone healthBone and Bones030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicineBone MarrowInternal medicinemedicineOverall survivalHumansRadiology Nuclear Medicine and imagingRadium-223 DichlorideNeoplasm MetastasisAgedL-Lactate DehydrogenaseRadiological and Ultrasound Technologybusiness.industrymCRPCAlkaline Phosphataseprostate cancermedicine.diseaseSurvival AnalysisRANK Ligand InhibitorProstatic Neoplasms Castration-ResistantDenosumabMulticenter studybone health agents030220 oncology & carcinogenesisSettore SECS-S/01businessRadiummedicine.drugInternational Journal of Radiation Biology
researchProduct

Radium-223 in mCPRC patients: a large real-life Italian multicenter study

2020

Background Radium-223 is a targeted alpha-particles therapy approved for the treatment of mCRPC patients with symptomatic bone metastases. To our knowledge we account for the largest cohort of mCRPC patients subjected to Radium-223 treatment in our country. We aim to describe in a real-life setting the largest cohort of mCRPC patients treated with Radium-223 ever taken into consideration. Methods 430 consecutive mCRPC patients were enrolled. Clinical data have been collected at baseline and at the end of the Radium-223 treatment. Furthermore, the overall survival(OS) of our population has been provided. Results 157 patients (36.5%) were still alive at the time of data analysis. A mean numbe…

MaleRadium-223radium-223; mCRPC; prostate cancer; target alpha therapyPediatricsmedicine.medical_specialtyradium-223UrologyPopulationBone NeoplasmsContext (language use)Quality of lifemedicineHumanseducationeducation.field_of_studybusiness.industrymCRPCprostate cancerProstatic Neoplasms Castration-ResistantRegimenSafety profileTreatment OutcomeItalyMulticenter studyNephrologyCohortQuality of LifeSettore SECS-S/01businesstarget alpha therapyRadiummedicine.drugMinerva Urology and Nephrology
researchProduct

PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients

2007

Microscopic foci of prostatitis may induce prostate-specific antigen (PSA) increase. PSA reduction after antibiotics might identify those patients in whom biopsy can be avoided. Ninety-nine patients received ciprofloxacin for 3 weeks, of whom 59 showed PSA reduction. Histology detected small foci of prostatitis in 65% of cases. Carcinoma was found in 40 and 20.3% of patients with unchanged or decreased PSA, respectively (P=0.03). No cancer was detected if PSA decreased below 4 ng/ml or more than 70%. Biopsy can be postponed, with a low risk of missing a cancer, if PSA decreases more than 70% or below 4 ng/ml.

MaleRiskCancer Researchmedicine.medical_specialtyTime FactorsProstate biopsymedicine.drug_classUrologyAntibioticsUrologyProstatitisUnnecessary Proceduresurologic and male genital diseasesSettore MED/24 - UrologiaDiagnosis DifferentialProstate cancerCiprofloxacinBiopsyCarcinomaHumansMedicineUltrasonography InterventionalAgedAged 80 and overPalpationmedicine.diagnostic_testbusiness.industryPatient SelectionBiopsy NeedleProstateProstatic NeoplasmsCancerHistologyOrgan SizeMiddle AgedProstate-Specific Antigenmedicine.diseaseAnti-Bacterial AgentsProstatitisOncologybusinessprostate-specific antigen (PSA) prostatitis prostate carcinomaFollow-Up Studies
researchProduct

Consumption of Fish and ω-3 Fatty Acids and Cancer Risk: An Umbrella Review of Meta-Analyses of Observational Studies

2020

Multiple studies have suggested that ω-3 fatty acid intake may have a protective effect on cancer risk; however, its true association with cancer risk remains controversial. We performed an umbrella review of meta-analyses to summarize and evaluate the evidence for the association between ω-3 fatty acid intake and cancer outcomes. We searched PubMed, Embase, and the Cochrane Database of Systematic Reviews from inception to December 1, 2018. We included meta-analyses of observational studies that examined associations between intake of fish or ω-3 fatty acid and cancer risk (gastrointestinal, liver, breast, gynecologic, prostate, brain, lung, and skin) and determined the level of evidence of…

MaleRiskOncologymedicine.medical_specialty[SDV]Life Sciences [q-bio]BFMedicine (miscellaneous)ReviewCohort Studies03 medical and health sciencesProstate cancer0302 clinical medicineBreast cancerω-3 fatty acidMeta-Analysis as TopicNeoplasmsInternal medicineFatty Acids Omega-3medicineAnimalsHumanscancer030212 general & internal medicineω-3 fatty acid fish cancer umbrella review meta-analysischemistry.chemical_classificationfishNutrition and Dieteticsumbrella reviewbusiness.industryEndometrial cancerFishesFatty acidCancermedicine.diseaseR13. Good healthmeta-analysisObservational Studies as TopicchemistryCase-Control Studies030220 oncology & carcinogenesisMeta-analysisFemaleSkin cancerbusinessLiver cancerFood Science
researchProduct